InflaRx IFRX

InflaRx N. V. is a biopharmaceutical company focused on discovering developing and commercializing first in class inhibitors of the complement activation factor C5a and its receptor C5aR to treat autoimmune and inflammatory diseases by targeting the C5a/C5aR1 signaling axis.

The company generates revenue primarily through the commercial sales of its approved product vilobelimab marketed as GOHIBIC for the treatment of critically ill invasively mechanically ventilated COVID 19 patients with SARS CoV 2 induced ARDS who are receiving systemic corticosteroids and invasive mechanical ventilation with or without ECMO under marketing authorization granted by the European Commission under exceptional circumstances.

The company operates through the following segments:

• Vilobelimab: This segment focuses on the development and commercialization of vilobelimab an intravenously administered monoclonal antibody that selectively binds to free C5a to inhibit its inflammatory activity while preserving membrane attack complex formation. Vilobelimab has received marketing authorization in the European Union for the treatment of adult patients with SARS CoV 2 induced ARDS who are receiving systemic corticosteroids and invasive mechanical ventilation with or without ECMO and is commercially available in the United States under an Emergency Use Authorization from the FDA for critically ill invasively mechanically ventilated COVID 19 patients.
• Izicopan: This segment focuses on the development of izicopan formerly known as INF904 an orally administered small molecule inhibitor of the C5a receptor C5aR1. Izicopan is being developed for chronic autoimmune and inflammatory conditions such as hidradenitis suppurativa and chronic spontaneous urticaria where an oral therapeutic is preferred for long term patient management. The company has completed Phase 1 clinical trials and reported positive Phase 2a data in HS and CSU patients in November 2025.
• IFX002: This segment focuses on the preclinical development of IFX002 a highly potent anti C5a antibody with a higher humanization grade and altered pharmacokinetic properties compared to vilobelimab. IFX002 binds to the same epitope on free C5a as vilobelimab and is intended as a life cycle management product for vilobelimab given its longer remaining patent life and potential suitability for chronic inflammatory indications requiring less frequent dosing.

InflaRx N. V. operates in a niche within the biopharmaceutical industry targeting the complement system specifically the C5a/C5aR1 signaling axis where it holds a first mover advantage as the only company with an approved drug vilobelimab that directly inhibits C5a. The company faces competition from established therapies such as adalimumab secukinumab and bimekizumab for hidradenitis suppurativa omalizumab dupilumab and remibrutinib for chronic spontaneous urticaria and corticosteroids IL 1 and IL 6 inhibitors and JAK inhibitors for critically ill COVID 19 patients but maintains a competitive edge through its proprietary technology that enables specific C5a inhibition without compromising upstream complement functions or membrane attack complex formation.

The company serves hospitals and patients suffering from autoimmune and inflammatory diseases including those with severe COVID 19 induced ARDS hidradenitis suppurativa and chronic spontaneous urticaria. Its commercial product vilobelimab is available for ordering by hospitals in the United States under the EUA and is intended for use in critically ill invasively mechanically ventilated patients in intensive care settings.